Deutsche Bank AG Purchases 174,944 Shares of Quest Diagnostics Incorporated (NYSE:DGX)

Deutsche Bank AG raised its position in Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 35.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 666,043 shares of the medical research company's stock after acquiring an additional 174,944 shares during the quarter. Deutsche Bank AG owned approximately 0.60% of Quest Diagnostics worth $100,479,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in DGX. Price T Rowe Associates Inc. MD raised its position in Quest Diagnostics by 42.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,490,278 shares of the medical research company's stock worth $828,265,000 after acquiring an additional 1,637,525 shares during the period. Norges Bank bought a new stake in shares of Quest Diagnostics during the 4th quarter valued at $191,823,000. JPMorgan Chase & Co. increased its stake in shares of Quest Diagnostics by 60.4% in the 4th quarter. JPMorgan Chase & Co. now owns 2,433,913 shares of the medical research company's stock worth $367,180,000 after purchasing an additional 916,898 shares in the last quarter. Alliancebernstein L.P. raised its holdings in Quest Diagnostics by 83.7% in the 4th quarter. Alliancebernstein L.P. now owns 1,093,042 shares of the medical research company's stock worth $164,896,000 after purchasing an additional 497,995 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in Quest Diagnostics during the fourth quarter valued at $67,447,000. 88.06% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Quest Diagnostics

In other Quest Diagnostics news, CEO J. E. Davis sold 39,191 shares of Quest Diagnostics stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $168.46, for a total transaction of $6,602,115.86. Following the completion of the transaction, the chief executive officer now directly owns 127,623 shares of the company's stock, valued at $21,499,370.58. The trade was a 23.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael E. Prevoznik sold 604 shares of the business's stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $170.99, for a total transaction of $103,277.96. Following the transaction, the senior vice president now owns 39,845 shares in the company, valued at $6,813,096.55. This trade represents a 1.49% decrease in their position. The disclosure for this sale can be found here. Insiders sold 54,250 shares of company stock worth $9,188,295 over the last 90 days. 8.16% of the stock is owned by insiders.

Quest Diagnostics Price Performance

Shares of Quest Diagnostics stock opened at $176.96 on Monday. The firm has a market cap of $19.75 billion, a PE ratio of 23.01, a PEG ratio of 2.16 and a beta of 0.52. The stock has a 50 day moving average of $169.70 and a 200 day moving average of $162.96. The company has a current ratio of 1.10, a quick ratio of 1.02 and a debt-to-equity ratio of 0.82. Quest Diagnostics Incorporated has a 12 month low of $135.47 and a 12 month high of $179.32.

Quest Diagnostics (NYSE:DGX - Get Free Report) last posted its earnings results on Tuesday, April 22nd. The medical research company reported $2.21 EPS for the quarter, beating analysts' consensus estimates of $2.15 by $0.06. Quest Diagnostics had a return on equity of 15.07% and a net margin of 8.80%. The firm had revenue of $2.65 billion during the quarter, compared to the consensus estimate of $2.63 billion. On average, research analysts expect that Quest Diagnostics Incorporated will post 9.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Mizuho raised their price objective on Quest Diagnostics from $178.00 to $189.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 9th. Citigroup cut shares of Quest Diagnostics from a "buy" rating to a "neutral" rating and set a $185.00 target price on the stock. in a research note on Tuesday, March 4th. Truist Financial lifted their price target on shares of Quest Diagnostics from $182.00 to $190.00 and gave the company a "hold" rating in a report on Wednesday, April 23rd. Redburn Atlantic initiated coverage on shares of Quest Diagnostics in a research note on Wednesday, April 2nd. They issued a "buy" rating and a $195.00 price objective for the company. Finally, Piper Sandler lifted their target price on shares of Quest Diagnostics from $180.00 to $200.00 and gave the company a "neutral" rating in a research note on Monday, April 28th. Eight research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, Quest Diagnostics has an average rating of "Moderate Buy" and an average price target of $185.73.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.